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those of supervoltage radiation. The beam must have a good output and be well collimated so that wedge filters, shields and a wide range of field sizes can be used and give flexibility and precision of treatment. Without these provisos, there could be a grave risk of putting fast neutrons at clinical and technical disadvantages and of obtaining misleading results of their therapeutic value. 
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Problems with Neutron Therapy
Investigations with neutrons and other high linear energy transfer (LET) radiations represent one of the growing points in radiotherapy. We should like to know whether high LET radiation brings about a regression in a higher percentage of tumours and if it has a place in the treatment of human cancer. If so, which tumours are most suitable for treatment, what fractionation should be used and whether there may be an advantage in using high LET with low LET radiation as was suggested by Thomlinson (1971) . Some of these questions will take years to elucidate. A great many centres are thinking of installing cyclotron and neutron generators in this country and overseas. A few major centres throughout the world are building large machines for-7r meson therapy. These particles possess the advantage of neutrons in overcoming the relative resistance of tumours due to anoxia and they have a better dose distribution. If anoxia is an important factor in the response of human tumours to radiation, as it appears to be in animal tumours, these large generators may ultimately have a place in therapy, but if there is no advantage to be obtained with neutrons then it is doubtful if the physical advantages alone would justify the high cost of a -n meson installation.
We know that X-and gamma-rays differ from high LET radiations in respect of three factors:
(1) the relative biological efficiency (RBE); (2) the oxygen enhancement ratio, i.e. the extent to which oxygen enhances the radiation effect;
(3) the capacity for recovery of sublethal radiation damage. Neutrons will be advantageous only if one or more of these factors results in increased damage to tumour compared with damage to normal surrounding tissues and blood vessels, provided that any advantage is not offset by some disadvantage. Although data are available about the behaviour of animal tumours there is no information on the effect of neutrons on human tumours. From the animal studies we know that the RBE is not a fixed relationship but depends on a number of factors such as the size of the dose fraction, the type of tumour and the nature of the normal tissue irradiated. It also depends on the state of oxygenation of the cells at the time of the radiation and the change in oxygenation during a course of fractionated radiotherapy. The RBE for acute radiation effects on the epithelial tissue and the late effects, which are mainly vascular, may also differ.
The evidence which has been produced from animal experiments suggests that the RBE values for neutrons are greater in tumours than in normal tissues within the therapeutic dose range. The findings suggest that there may be a gain of 1.2-1.3, i.e. a 20-30% increase in the effective dose to the tumour compared with the dose to normal tissues. This may not seem very great but we know that in some tumours a small increase in dose may make a large difference in the tumour control rates.
Although the evidence is not very substantial it is in favour of there being definite advantages in the use of neutrons. Therefore an attempt to use this radiation in a trial would seem to be a justifiable procedure.
(1) PhysicalProblems In comparing neutrons and X-rays ideally we should ensure that the physical distribution of the two radiations is similar. If the isodose curves of the 7 MeV neutron and the 8 MeV linear accelerator beams are compared it will be seen that the edge of the neutron beam is not quite so well defined, the depth dose is less and there is also less skin sparing. As practical radiotherapists we might consider that the distribution of the radiation in the neutron beam is inferior to that in the linear accelerator beam, particularly when treating deep-seated tumours.
In the most efficient therapy the aim is to deliver a specified dose to the tumour and to minimize the total dose given to the normal tissues and the body as a whole. Table 1 gives the -total integral dose per 1000 rads to the tumour using a 4-field technique in bladder cancer, treated by different types of radiations. It is seen that the integral dose is highest for the 250 kV radiation and for neutrons it lies somewhere between 250 kV and cobalt therapy. Although the exact biological significance of this observation is uncertain it does indicate that there is a greater deposition of radiation energy outside the tumour than there is with supervoltage X-ray therapy. This difference would not be so great for superficial tumours, however. A further point of importance is that the RBE for the radiation outside the tumour may be relatively greater than in the tumour area because of the lower dose rate.
(2) The Clinical and Biological Problem The tumours which we should like to select for neutron therapy are those which have a relatively high component of anoxic cells. Unfortunately, we do not have this information although some ideas may be gained from the histological sections. For example, where there are foci of necrosis the adjacent zones may be expected to contain anoxic tissue.
Tumours most suitable for trial are those which do not disseminate readily and in which there is a high local failure rate. It is also an advantage to treat tumours which can be easily observed and and in which a satisfactory dose distribution can be obtained. Primary cancer of the oral cavity, of the pharynx and of the larynx with or without secondary nodes in the neck are the groups which meet these criteria and seem the ideal cases for a clinical trial. Dr Catterall has also given examples of tumours which' are not normally treated by radiotherapy (p 839). This is an important study as there may be other factors involved in the radiation response in addition to those which are known.
A further important clinical factor is the tolerance of the normal tissues to fractionated neutron radiations. The response of the intestine, for example, to X-rays is governed by the large capacity for repair of sublethal damage exhibited by the stem cells of the intestinal mucosa after X-ray exposure. If this protective repair capacity were reduced disproportionately by neutron irradiation we might expect serious bowel reaction and it would then be necessary to exclude the bowel from the field of radiation. Other normal tissues which may suffer increased damage are those which are partially protected by some degree of anoxia in X-ray therapy but would not be so well')protected when neutrons were given: for example, cartilage, bone and the spinal cord.
(3) Statistical Problems A further important consideration is the number of patients required to show a difference in results ( Table 2) . As well as having a sufficient number of patients in the clinical trial it is also important to ensure that similar cases are compared and a system of pairing has to be adopted. The stricter the criteria for pairing the cases, the more difficult does it become to get a sufficient number of comparable pairs. More sophisticated statistical techniques have been devised to try and obtain convincing answers with fewer patients. One problem of the controlled trial in cancer therapy is the time that it takes to complete because the difference between methods is usually small and the number of patients required is quite large. Sometimes the clinician has already formed an opinion about the value of the treatment under trial before the results are statistically significant and the trial has then to be abandoned.
(4) Ethical Considerations
The question must be asked how justifiable it is to include patients in a trial in which an unknown method is being matched against one where the results are already established. It would be unethical to include patients in whom the chance of survival with conventional treatment is fairly good, but reasonable if the chance is poor. The question arises at what level it becomes ethical to accept patients. This is a decision which can only be made by each clinician based on his past experience.
